Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study

Objective: Cost-minimization analysis of onabotulinumtoxinA and abobotulinumtoxinA, taking into account the real dose administered to children with spasticity associated with dynamic equinus foot deformity due to cerebral palsy. Method: A single centre, observational, longitudinal, and retrospective study which included spastic paediatric patients aged 2-to-18-years and treated with onabotulinumtoxinA or abobotulinumtoxinA from December 1995 to October 2012, in the Paediatric Neurology Unit of a first-level Spanish hospital. A longitudinal analysis of spasticity severity was made to confirm the similar effectiveness of both treatments. Cost minimization was analyzed using the dose administered and the direct costs (pharmacological and medical visits costs) from the perspective of the National Health System (in 2016 euros). Results: We analyzed 895 patients with paediatric spasticity: 543 were treated only with onabotulinumtoxinA, 292 only with abobotulinumtoxinA, and 60 with both treatments. The mean doses administered were 5.44 U/kg (SD = 2.17) for onabotulinumtoxinA, and 14.73 U/kg (5.26) for abobotulinumtoxinA. The total annual direct cost (pharmacological and medical visits) was € 839.56 for onabotulinumtoxinA and € 631.23 for abobotulinumtoxinA, which represents a difference of € 208.34 per year in favour of treatment with abobotulinum-toxinA. Conclusions: It has been shown that in real clinical practice, the cost per patient and year for treatment of paediatric spasticity was lower when abobotulinumtoxinA was used.

Saved in:
Bibliographic Details
Main Authors: Tapias,Gloria, García-Romero,Mar, Crespo,Carlos, Cuesta,Maribel, Forné,Carles, Pascual-Pascual,Samuel Ignacio
Format: Digital revista
Language:English
Published: Grupo Aula Médica 2016
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432016000500007
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-63432016000500007
record_format ojs
spelling oai:scielo:S1130-634320160005000072017-02-28Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective studyTapias,GloriaGarcía-Romero,MarCrespo,CarlosCuesta,MaribelForné,CarlesPascual-Pascual,Samuel Ignacio Botulinum toxins Paediatric spasticity Clinical practice dose Equinus foot Spain Objective: Cost-minimization analysis of onabotulinumtoxinA and abobotulinumtoxinA, taking into account the real dose administered to children with spasticity associated with dynamic equinus foot deformity due to cerebral palsy. Method: A single centre, observational, longitudinal, and retrospective study which included spastic paediatric patients aged 2-to-18-years and treated with onabotulinumtoxinA or abobotulinumtoxinA from December 1995 to October 2012, in the Paediatric Neurology Unit of a first-level Spanish hospital. A longitudinal analysis of spasticity severity was made to confirm the similar effectiveness of both treatments. Cost minimization was analyzed using the dose administered and the direct costs (pharmacological and medical visits costs) from the perspective of the National Health System (in 2016 euros). Results: We analyzed 895 patients with paediatric spasticity: 543 were treated only with onabotulinumtoxinA, 292 only with abobotulinumtoxinA, and 60 with both treatments. The mean doses administered were 5.44 U/kg (SD = 2.17) for onabotulinumtoxinA, and 14.73 U/kg (5.26) for abobotulinumtoxinA. The total annual direct cost (pharmacological and medical visits) was € 839.56 for onabotulinumtoxinA and € 631.23 for abobotulinumtoxinA, which represents a difference of € 208.34 per year in favour of treatment with abobotulinum-toxinA. Conclusions: It has been shown that in real clinical practice, the cost per patient and year for treatment of paediatric spasticity was lower when abobotulinumtoxinA was used.Grupo Aula MédicaFarmacia Hospitalaria v.40 n.5 20162016-10-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432016000500007en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Tapias,Gloria
García-Romero,Mar
Crespo,Carlos
Cuesta,Maribel
Forné,Carles
Pascual-Pascual,Samuel Ignacio
spellingShingle Tapias,Gloria
García-Romero,Mar
Crespo,Carlos
Cuesta,Maribel
Forné,Carles
Pascual-Pascual,Samuel Ignacio
Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
author_facet Tapias,Gloria
García-Romero,Mar
Crespo,Carlos
Cuesta,Maribel
Forné,Carles
Pascual-Pascual,Samuel Ignacio
author_sort Tapias,Gloria
title Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
title_short Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
title_full Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
title_fullStr Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
title_full_unstemmed Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
title_sort cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type a: an observational, longitudinal, retrospective study
description Objective: Cost-minimization analysis of onabotulinumtoxinA and abobotulinumtoxinA, taking into account the real dose administered to children with spasticity associated with dynamic equinus foot deformity due to cerebral palsy. Method: A single centre, observational, longitudinal, and retrospective study which included spastic paediatric patients aged 2-to-18-years and treated with onabotulinumtoxinA or abobotulinumtoxinA from December 1995 to October 2012, in the Paediatric Neurology Unit of a first-level Spanish hospital. A longitudinal analysis of spasticity severity was made to confirm the similar effectiveness of both treatments. Cost minimization was analyzed using the dose administered and the direct costs (pharmacological and medical visits costs) from the perspective of the National Health System (in 2016 euros). Results: We analyzed 895 patients with paediatric spasticity: 543 were treated only with onabotulinumtoxinA, 292 only with abobotulinumtoxinA, and 60 with both treatments. The mean doses administered were 5.44 U/kg (SD = 2.17) for onabotulinumtoxinA, and 14.73 U/kg (5.26) for abobotulinumtoxinA. The total annual direct cost (pharmacological and medical visits) was € 839.56 for onabotulinumtoxinA and € 631.23 for abobotulinumtoxinA, which represents a difference of € 208.34 per year in favour of treatment with abobotulinum-toxinA. Conclusions: It has been shown that in real clinical practice, the cost per patient and year for treatment of paediatric spasticity was lower when abobotulinumtoxinA was used.
publisher Grupo Aula Médica
publishDate 2016
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432016000500007
work_keys_str_mv AT tapiasgloria costminimizationanalysisinthetreatmentofspasticityinchildrenwithcerebralpalsywithbotulinumtoxintypeaanobservationallongitudinalretrospectivestudy
AT garciaromeromar costminimizationanalysisinthetreatmentofspasticityinchildrenwithcerebralpalsywithbotulinumtoxintypeaanobservationallongitudinalretrospectivestudy
AT crespocarlos costminimizationanalysisinthetreatmentofspasticityinchildrenwithcerebralpalsywithbotulinumtoxintypeaanobservationallongitudinalretrospectivestudy
AT cuestamaribel costminimizationanalysisinthetreatmentofspasticityinchildrenwithcerebralpalsywithbotulinumtoxintypeaanobservationallongitudinalretrospectivestudy
AT fornecarles costminimizationanalysisinthetreatmentofspasticityinchildrenwithcerebralpalsywithbotulinumtoxintypeaanobservationallongitudinalretrospectivestudy
AT pascualpascualsamuelignacio costminimizationanalysisinthetreatmentofspasticityinchildrenwithcerebralpalsywithbotulinumtoxintypeaanobservationallongitudinalretrospectivestudy
_version_ 1755939076039507968